Bonum Therapeutics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies

Details:

The Series A financing will allow Bonum to apply the technology to regulated cytokines, including IL-12, IFN-alpha, and TGF-beta for immuno-oncology applications.

Lead Product(s): PDL1 Dependent INF-alpha Therapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Large molecule

Partner/Sponsor/Collaborator: Roche Venture Fund

Deal Size: $93.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing November 15, 2022

ASK
US

Upload
your Marketing & Sales content

Bonum Therapeutics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

Details:

The acquisition will give Roche rights to Good Therapeutics’ innovative, conditionally active, PD-1-regulated IL-2 program and an exclusive right to the platform technology for the development of PD-1-regulated IL-2 receptor agonist therapeutics.

Lead Product(s): PD-1-targeted IL-2 Therapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Large molecule

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: Undisclosed Upfront Cash: $250.0 million

Deal Type: Acquisition September 07, 2022

ASK
US

Upload
your Marketing & Sales content